Painkiller trial raises questions for FDA, Pfizer

By Shannon Brownlee and Jeanne Lenzer

In February 2005, the U.S. Food and Drug Administration (FDA) called a three-day hearing to review the risks of three painkillers known as C

Related to this story

Heart testing bill signed by Perry required unnecessary tests, critics charge

By Rochelle Sharpe

Drug makers' dime funds Congressional travel

By Robert Brodsky

More big money from pharmaceutical lobby in 2008

By Mary Beth Lombardo

Checkbook politics

By Victoria Kreha

Excerpts from this story referencing "Garret FitzGerald":

"… fect was to make the non-selective NSAIDs seem as risky as the COX-2s. Dr. Garret FitzGerald, professor of medicine and pharmacology at the University of Pennsylvania, …"